Clinical Trial: AST-120 (Kremezin(R)) for the Renal Protection and Attenuation of Decline in Acute Kidney Disease

U.S., Sept. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07182422) titled 'AST-120 (Kremezin(R)) for the Renal Protection and Attenuation of Decline in Acute Kidney Disease' on Sept. 04.

Brief Summary: The primary goal of this clinical trial is to evaluate the efficacy of AST-120 (Kremezin(R)) in combination with standard care in reducing the levels of protein-bound uremic toxins (PBUTs), specifically indoxyl sulfate (IS) and p-cresyl sulfate (p-CS), in patients with acute kidney disease (AKD). The trial aims to assess whether AST-120 can prevent further renal deterioration and slow the progression from AKD to chronic kidney disease (CKD) by mitigating the accumulation of PBUTs. Additionally, the study wi...